• Publications
  • Influence
The urokinase‐type plasminogen activator system in cancer metastasis: A review
Recent observations related to the molecular and cellular mechanisms underlying the role of the u‐PA system are discussed, suggesting that the system does not support tumor metastasis by the unrestricted enzyme activity of u‐ PA and plasmin and that pericellular molecular and functional interactions appear to allow temporal and spatial re‐organizations of the system during cell migration. Expand
Metalloproteinases: role in breast carcinogenesis, invasion and metastasis
Because MMPs are apparently involved in breast cancer initiation and dissemination, inhibition of these proteinases may be of value both in preventing breast cancer and in blocking metastasis of established tumours. Expand
Activated Phosphoinositide 3-Kinase/AKT Signaling Confers Resistance to Trastuzumab but not Lapatinib
Investigation of the role of receptor tyrosine kinase signaling and phosphoinositide 3-kinase (PI3K)/AKT pathway activation in conferring resistance to trastuzumab and lapatinib concluded that pharmacologic targeting of the PI3K/AKT pathways may provide benefit to HER2-positive breast cancer patients who are resistant totrastuzuab therapy. Expand
Carcinoembryonic antigen as a marker for colorectal cancer: is it clinically useful?
  • M. Duffy
  • Medicine
  • Clinical chemistry
  • 1 April 2001
Overall, little evidence is available that monitoring of all patients with diagnosed colorectal cancer leads to enhanced patient outcome or quality of life, and high preoperative concentrations of CEA correlate with adverse prognosis. Expand
Tumour markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines for clinical use.
New guidelines for the use of serum, tissue and faecal markers in colorectal cancer (CRC) are presented and insufficient evidence exists to recommend routine use of tissue factors such as thymidylate synthase, microsatellite instability, p53, K-ras and deleted in colon cancer (DCC). Expand
The urokinase plasminogen activator system: role in malignancy.
  • M. Duffy
  • Biology, Medicine
  • Current pharmaceutical design
  • 2004
Assay of uPA and PAI-1 may help identify low risk node-negative patients for whom adjuvant chemotherapy is unnecessary, and preclinical studies show that either inhibition of u PA catalytic activity or prevention of UPA binding to its receptor reduces tumor growth, angiogenesis and metastasis. Expand
Tumor markers in pancreatic cancer: a European Group on Tumor Markers (EGTM) status report.
In patients with resectable pancreatic cancer, presurgical and postresection CA 19-9 levels correlate with overall survival and thus may be combined with other factors for risk stratification, and most, but not all, reports indicate that serial levels of CA19-9 correlate with response to systemic therapy. Expand
Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients.
For patients with lymph node-negative breast cancer, uPA and PAI-1 measurements in primary tumors may be especially useful for designing individualized treatment strategies. Expand
The urokinase plasminogen activator system: a rich source of tumour markers for the individualised management of patients with cancer.
Emerging data suggest that high levels of uPA and PAI-1 in breast cancer are associated with a preferential response to adjuvant chemotherapy but relative resistance to hormone therapy. Expand
National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers.
Recommendations to encourage optimal use of tumor markers for 5 cancer sites were critically reviewed and alpha-fetoprotein, human chorionic gonadotropin, and lactate dehydrogenase are recommended for diagnosis/case finding, staging, prognosis determination, recurrence detection, and therapy monitoring. Expand